Journal of Literature Pharmacy Sciences

Streptococcus pneumoniae Infections in Cancer Patients and the Role of the Pharmacist in Pneumococcal Vaccination: Traditional Review
Kanser Hastalarında Streptococcus pneumoniae Enfeksiyonları ve Eczacının Pnömokok Aşılamasındaki Rolü: Geleneksel Derleme
Nesligül ÖZDEMİRa, Aygin BAYRAKTAR EKİNCİOĞLUa
aDepartment of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Ankara, Türkiye
J Lit Pharm Sci. 2022;11(3):221-30
doi: 10.5336/pharmsci.2022-92730
Article Language: EN
Full Text
ABSTRACT
 Cancer patients are one of the susceptible populations at risk of infections due to intensive and immune response-altering treatments. Among the infections, Streptococcus pneumoniae-related infections have a significant impact on cancer patients. These infections can be seen as mild or invasive type which varies in severity according to the type of cancer. Invasive pneumococcal disease is a serious infection that increases morbidity and mortality in cancer patients. Ensuring the integrity of patients' immunity is essential in order to maintain safe and effective cancer treatment processes. International guidelines and health authorities recommend that cancer patients should receive pneumococcal vaccines against pneumococcal diseases. The administration of vaccines in cancer patients is more complicated than in any other patient groups due to ongoing immunosuppressive treatments, which results in not achieved desired rates in pneumococcal vaccination. The vaccination process requires comprehensive assessment of the factors directly related with cancer, such as cancer type/diagnosis, cancer stage, type of treatment and scheduled treatment along with other patient-related factors. Sustainability of immunization in adult population can be achieved by implementation of vaccination programs, although logistics, economic, social, and epidemiological factors hinder its implementation. In order to increase the vaccination rates, health professionals should work in cooperation with the patient. Pharmacists, as healthcare professionals, have contributed to increased vaccination rates in cancer patients by providing vaccine consultancy and as vaccine practitioners in some countries. This review focuses on pneumococcal infections observed in cancer patients, vaccination process, and pharmacist's role in vaccination.

Keywords: Cancer survivors; Streptococcus pneumoniae infections; pharmacist; vaccination
ÖZET
 Kanser hastaları, almış oldukları yoğun ve bağışıklık yanıtını değiştiren tedaviler nedeniyle enfeksiyon riski altındaki duyarlı popülasyonlardan biridir. Bu enfeksiyonlar arasında Streptococcus pneumoniae enfeksiyonları kanser hastalarında önemli bir etkiye sahiptir. Bu enfeksiyonlar, kanserin tipine göre şiddeti değişen hafif veya invaziv tipte görülebilmektedir. İnvaziv pnömokok hastalığı, kanser hastalarında morbidite ve mortaliteyi artıran ciddi bir enfeksiyondur. Güvenli ve etkili kanser tedavi süreçlerini sürdürmek için hastaların bağışıklığının bütünlüğünü sağlamak çok önemlidir. Uluslararası kılavuzlar ve sağlık otoriteleri, kanser hastalarının pnömokok hastalıklarına karşı pnömokok aşısı ile aşılanmalarını önermektedir. Kanser hastalarında aşıların uygulanması, devam eden immünsupresif tedaviler nedeniyle diğer hasta gruplarına göre daha karmaşıktır ve bu da pnömokok aşısıyla aşılamada istenilen oranlara ulaşılamaması ile sonuçlanmaktadır. Aşılama süreci, kanser türü, kanser tanısı, kanser evresi, tedavi türü ve planlanan tedavi süreci gibi kanserle doğrudan ilişkili faktörlerin ve hastayla ilgili diğer faktörlerin kapsamlı bir değerlendirmesini gerektirmektedir. Lojistik, ekonomik, sosyal ve epidemiyolojik faktörler aşı uygulanması önündeki bariyerler olsa da erişkin popülasyonda bağışıklamanın sürdürülebilirliği, aşılama programlarının uygulanmasıyla sağlanabilmektedir. Aşılanma oranlarının artması için sağlık profesyonellerinin hasta ile iş birliği içerisinde çalışması gerekmektedir. Eczacılar, sağlık profesyonelleri olarak, aşı danışmanlığı yaparak ve bazı ülkelerde aşı uygulayıcısı olarak kanser hastalarında aşı oranlarının artmasına katkıda bulunmaktadır. Bu derleme, kanser hastalarında gözlenen pnömokok enfeksiyonları, aşılama süreci ve eczacının aşılamadaki rolüne odaklanmaktadır.

Anahtar Kelimeler: Kanser survivorları; Streptococcus pneumoniae enfeksiyonları; eczacılar; aşılama
REFERENCES:
  1. Cancer World Health Organization [Internet]. © 2021 WHO. [Cited: July 24, 2021]. Cancer. Available from: [Link] 
  2. National Institutes of Health (US); Biological Sciences Curriculum Study. NIH Curriculum Supplement Series. Bethesda (MD): National Institutes of Health (US). Understanding Cancer [Internet]. Cited: Jun 29, 2021. Available from: [Link] 
  3. Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, et al. Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Semin Cancer Biol. 2015;35 Suppl(Suppl):S25-S54. [Crossref]  [PubMed]  [PMC] 
  4. Cooper GM. The Cell: A Molecular Approach. 2nd ed. Massachusetts: Sinauer Associates; 2000.
  5. World Health Organization [Internet]. © 2021 WHO. [Cited: Agust 12, 2021]. Cancer 2018. Available from: [Link] 
  6. World Health Organization. Global Cancer Observatory-Turkey 2020. Cited: Agust 12, 2021. Available from: [Link] 
  7. National Cancer Control Indicators [Internet]. © 2021 - CANCER AUSTRALIA. [Cited: Agust 15, 2021]. Relative Survival Rates-5 year relative survival 2020. Available from: [Link] 
  8. Blimark C, Holmberg E, Mellqvist UH, Landgren O, Björkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107-13. [Crossref]  [PubMed]  [PMC] 
  9. Pagano L, Caira M, Rossi G, Tumbarello M, Fanci R, Garzia MG, et al; Hema e-Chart Group, Italy. A prospective survey of febrile events in hematological malignancies. Ann Hematol. 2012;91(5):767-74. [Crossref]  [PubMed] 
  10. Marin M, Gudiol C, Ardanuy C, Garcia-Vidal C, Calvo M, Arnan M, et al. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours. J Infect. 2014;69(5):417-23. [Crossref]  [PubMed] 
  11. Lustberg MB. Management of neutropenia in cancer patients. Clin Adv Hematol Oncol. 2012;10(12):825-6. [PubMed]  [PMC] 
  12. Wong JL, Evans SE. Bacterial pneumonia in patients with cancer: novel risk factors and management. Clin Chest Med. 2017;38(2):263-77. [Crossref]  [PubMed]  [PMC] 
  13. Ocal N, Bilgiç H, Ucar E. Defence system of respiratory tract and clearence of inhalation agents. J Clin Anal Med. 2015;6:246-9.
  14. Carolia MN, Karen JV, Adachi JA. Bacterial colonization and host immunity. In: Safdar A, ed. Principles and Practice of Cancer Infectious Diseaes. 1st ed. New York: Humana Press; 2011.
  15. Zarco-Márquez S, Volkow-Fernández P, Velázquez-Acosta C, Echániz-Avilés G, Carnalla-Barajas MN, Soto-Noguerón A, et al. Invasive and complicated pneumococcal infection in patients with cancer. Rev Invest Clin. 2016;68(5):221-8. [PubMed] 
  16. Rolston KV. Infections in cancer patients with solid tumors: a review. Infect Dis Ther. 2017;6(1):69-83. [Crossref]  [PubMed]  [PMC] 
  17. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271(20):1598-601. [Crossref]  [PubMed] 
  18. Henriques-Normark B, Tuomanen EI. The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med. 2013;3(7):a010215. [Crossref]  [PubMed]  [PMC] 
  19. Loughran AJ, Orihuela CJ, Tuomanen EI. Streptococcus pneumoniae: invasion and inflammation. Microbiol Spectr. 2019;7(2):10.1128/microbiolspec.GPP3-0004-2018. [PubMed]  [PMC] 
  20. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4(3):144-54. [Crossref]  [PubMed] 
  21. Almeida ST, Pedro T, Paulo AC, de Lencastre H, Sá-Leão R. Re-evaluation of Streptococcus pneumoniae carriage in Portuguese elderly by qPCR increases carriage estimates and unveils an expanded pool of serotypes. Sci Rep. 2020;10(1):8373. [Crossref]  [PubMed]  [PMC] 
  22. Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16(6):355-67. [Crossref]  [PubMed]  [PMC] 
  23. World Health Organization [Internet]. [Cited: Agust 25, 2021]. Pneumococcal Disease 2015. Available from: [Link] 
  24. van Werkhoven CH, Huijts SM. Vaccines to prevent pneumococcal community-acquired pneumonia. Clin Chest Med. 2018;39(4):733-52. [Crossref]  [PubMed] 
  25. Garcia Garrido HM, Knol MJ, Heijmans J, van Sorge NM, Sanders EAM, Klümpen HJ, et al. Invasive pneumococcal disease among adults with hematological and solid organ malignancies: a population-based cohort study. Int J Infect Dis. 2021;106:237-45. [Crossref]  [PubMed] 
  26. Jung J, Moon SM, Jang HC, Kang CI, Jun JB, Cho YK, et al. Incidence and risk factors of postoperative pneumonia following cancer surgery in adult patients with selected solid cancer: results of "Cancer POP" study. Cancer Med. 2018;7(1):261-9. [Crossref]  [PubMed]  [PMC] 
  27. Johansson N, Kalin M, Hedlund J. Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Scand J Infect Dis. 2011;43(8):609-15. [Crossref]  [PubMed] 
  28. Dandachi D, Rodriguez-Barradas MC. Viral pneumonia: etiologies and treatment. J Investig Med. 2018;66(6):957-65. [Crossref]  [PubMed] 
  29. Pletz MW, Rohde GG, Welte T, Kolditz M, Ott S. Advances in the prevention, management, and treatment of community-acquired pneumonia. F1000Res. 2016;5:F1000 Faculty Rev-300. [Crossref]  [PubMed]  [PMC] 
  30. Daniels CC, Rogers PD, Shelton CM. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther. 2016;21(1):27-35. [Crossref]  [PubMed]  [PMC] 
  31. Berical AC, Harris D, Dela Cruz CS, Possick JD. Pneumococcal vaccination strategies. An update and perspective. Ann Am Thorac Soc. 2016;13(6):933-44. [Crossref]  [PubMed]  [PMC] 
  32. Türkiye Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Uzmanlık Derneği. Erişkin Bağışıklama Rehberi; 2016. [Link] 
  33. Principi N, Esposito S. Prevention of community-acquired pneumonia with available pneumococcal vaccines. Int J Mol Sci. 2016;18(1):30. [Crossref]  [PubMed]  [PMC] 
  34. Papadatou I, Tzovara I, Licciardi PV. The role of serotype-specific immunological memory in pneumococcal vaccination: current knowledge and future prospects. Vaccines (Basel). 2019;7(1):13. [Crossref]  [PubMed]  [PMC] 
  35. Robin C, Beckerich F, Cordonnier C. Immunization in cancer patients: where we stand. Pharmacol Res. 2015;92:23-30. [Crossref]  [PubMed] 
  36. Chang A, Ellingson MK, Flowers CR, Bednarczyk RA. Influenza vaccination rates among patients with a history of cancer: analysis of the national health interview survey. Open Forum Infect Dis. 2021;8(7):ofab198. [Crossref]  [PubMed]  [PMC] 
  37. Tsigrelis C, Ljungman P. Vaccinations in patients with hematological malignancies. Blood Rev. 2016;30(2):139-47. [Crossref]  [PubMed] 
  38. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44-100. [Crossref]  [PubMed] 
  39. Kang DH, Weaver MT, Park NJ, Smith B, McArdle T, Carpenter J. Significant impairment in immune recovery after cancer treatment. Nurs Res. 2009;58(2):105-14. [Crossref]  [PubMed]  [PMC] 
  40. Guzek A, Berghoff AS, Jasinska J, Garner-Spitzer E, Wagner A, Stiasny K, et al. Reduced seroprevalence against vaccine preventable diseases (VPDs) in adult patients with cancer: necessity of routine vaccination as part of the therapeutic concept. Ann Oncol. 2020;31(2):319-21. [Crossref]  [PubMed] 
  41. Centers for Disease Control and Prevention. General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) 2021. Cited: September 13, 2021. Available from: [Link] 
  42. Centers for Disease Control and Prevention [Internet]. [Cited: September 19, 2022]. Recommended Adult Immunization Schedule for ages 19 years or older 2021. Available from: [Link] 
  43. Wehbi NK, Wani RJ, Klepser DG, Murry J, Khan AS. Impact of implementing a technology platform in community pharmacies to increase adult immunizations rates. Vaccine. 2019;37(1):56-60. [Crossref]  [PubMed] 
  44. Isenor JE, Edwards NT, Alia TA, Slayter KL, MacDougall DM, McNeil SA, et al. Impact of pharmacists as immunizers on vaccination rates: a systematic review and meta-analysis. Vaccine. 2016;34(47):5708-23. [Crossref]  [PubMed] 
  45. Hattingh HL, Sim TF, Parsons R, Czarniak P, Vickery A, Ayadurai S. Evaluation of the first pharmacist-administered vaccinations in Western Australia: a mixed-methods study. BMJ Open. 2016;6(9):e011948. [Crossref]  [PubMed]  [PMC] 
  46. Poudel A, Lau ETL, Deldot M, Campbell C, Waite NM, Nissen LM. Pharmacist role in vaccination: Evidence and challenges. Vaccine. 2019;37(40):5939-45. [Crossref]  [PubMed] 
  47. International Pharmaceutical Federation (FIP). The FIP vaccination reference guide.Knowledge and skills to support professional development and inform pharmacy education in vaccination 2022. Cited: September 19, 2022. Available from: [Link] 
  48. Yemeke TT, McMillan S, Marciniak MW, Ozawa S. A systematic review of the role of pharmacists in vaccination services in low-and middle-income countries. Res Social Adm Pharm. 2021;17(2):300-6. [Crossref]  [PubMed] 
  49. Cassidy C, Langley J, Steenbeek A, Taylor B, Kennie-Kaulbach N, Grantmyre H, et al. A Behavioral analysis of nurses' and pharmacists' role in addressing vaccine hesitancy: scoping review. Hum Vaccin Immunother. 2021;17(11):4487-504. [Crossref]  [PubMed]  [PMC] 
  50. Sitte J, Frentiu E, Baumann C, Rousseau H, May T, Bronowicki JP, et al. Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: a prospective cohort study of methods for improving coverage. Aliment Pharmacol Ther. 2019;49(1):84-90. [Crossref]  [PubMed] 
  51. Toleman MS, Herbert K, McCarthy N, Church DN. Vaccination of chemotherapy patients--effect of guideline implementation. Support Care Cancer. 2016;24(5):2317-21. [Crossref]  [PubMed] 
  52. Delacruz W, Terrazzino S, Osswald M, Payne C, Haney B. Implementing a multidisciplinary approach to enhance compliance with guideline-recommended prechemotherapy pneumococcal vaccination in a military-based medical oncology practice. J Oncol Pract. 2017;13(11):e966-71. [Crossref]  [PubMed] 
  53. McGinnis JM, Jones R, Hillis C, Kokus H, Thomas H, Thomas J, et al. A pneumococcal pneumonia and influenza vaccination quality improvement program for women receiving chemotherapy for gynecologic cancers at a major tertiary cancer Centre. Gynecol Oncol. 2021;161(1):236-43. [Crossref]  [PubMed] 
  54. Church EC, Banks R, Wilson B, Arfons L, Perez F, Jump R. Improving pneumococcal vaccine uptake in veterans with chronic lymphocytic leukemia through a virtual clinic. Curr Oncol. 2018;25(1):e95-8. [Crossref]  [PubMed]  [PMC] 
  55. Goldsworthy J, Salvati L, Tomlin CR, Jenkins T, Jameson A, Dumkow LE. Impact of a pharmacist-led pneumococcal vaccination outreach program in a primary care setting. Journal of American Collage of Clinical Pharmacy. 2022;5:302-9. [Crossref] 
  56. Sheer RL, Nau DP, Dorich N, Boyer AD, Pickering M, Campbell PJ, et al. Medicare advantage-pharmacy partnership improves influenza and pneumococcal vaccination rates. Am J Manag Care. 2021;27(10):425-31. [Crossref]  [PubMed] 
  57. Abu-Rish EY, Barakat NA. The impact of pharmacist-led educational intervention on pneumococcal vaccine awareness and acceptance among elderly in Jordan. Hum Vaccin Immunother. 2021;17(4):1181-9. [Crossref]  [PubMed]  [PMC] 
  58. Caffrey AR, DeAngelis JM, Ward KE, Orr KK, Morrill HJ, Gosciminski M, et al; Rhode Island Pharmacy Pneumococcal Vaccination Education Group. A pharmacist-driven academic detailing program to increase adult pneumococcal vaccination. J Am Pharm Assoc (2003). 2018;58(3):303-10. [Crossref]  [PubMed] 
  59. Towards one FIP Working in trust and solidarity. International Pharmaceutical Federation Annual Report 2020. [Link] 
  60. The International Pharmaceutical Federation (FIP) [Internet]. © Copyright International Pharmaceutical Federation 2022. [Cited: September 19, 2022]. Transforming Vaccination Globally, Regionally and Nationally 2021. Available from: [Link] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com